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Developmental hypomyelination in
Wolfram syndrome: new insights from
neuroimaging and gene expression
analyses
Amjad Samara1, Rachel Rahn1,2,3, Olga Neyman1, Ki Yun Park1, Ahmad Samara4, Bess Marshall5,
Joseph Dougherty1,3 and Tamara Hershey1,2,6*

Abstract
Wolfram syndrome is a rare multisystem disorder caused by mutations in WFS1 or CISD2 genes leading to brain
structural abnormalities and neurological symptoms. These abnormalities appear in early stages of the disease. The
pathogenesis of Wolfram syndrome involves abnormalities in the endoplasmic reticulum (ER) and mitochondrial
dynamics, which are common features in several other neurodegenerative disorders. Mutations in WFS1 are
responsible for the majority of Wolfram syndrome cases. WFS1 encodes for an endoplasmic reticulum (ER) protein,
wolframin. It is proposed that wolframin deficiency triggers the unfolded protein response (UPR) pathway resulting
in an increased ER stress-mediated neuronal loss. Recent neuroimaging studies showed marked alteration in early
brain development, primarily characterized by abnormal white matter myelination. Interestingly, ER stress and the
UPR pathway are implicated in the pathogenesis of some inherited myelin disorders like Pelizaeus-Merzbacher
disease, and Vanishing White Matter disease. In addition, exploratory gene-expression network-based analyses
suggest that WFS1 expression occurs preferentially in oligodendrocytes during early brain development. Therefore,
we propose that Wolfram syndrome could belong to a category of neurodevelopmental disorders characterized by
ER stress-mediated myelination impairment. Further studies of myelination and oligodendrocyte function in
Wolfram syndrome could provide new insights into the underlying mechanisms of the Wolfram syndromeassociated brain changes and identify potential connections between neurodevelopmental disorders and
neurodegeneration.
Keywords: WFS1, endoplasmic reticulum stress, Unfolded protein response, Neuroimaging, Hypomyelination,
Neurodevelopment, Neurodegeneration

Background
Wolfram syndrome (OMIM #222300; previously known
as DIDMOAD) is a rare (1 in 500,000 to 1,000,000),
autosomal recessive disease initially described as a combination of early-onset diabetes mellitus, progressive
optic nerve atrophy, diabetes insipidus and sensorineural
hearing loss [1]. About two-thirds of the patients
* Correspondence: tammy@wustl.edu
1
Department of Psychiatry, Washington University School of Medicine, 4525
Scott Avenue, St. Louis, MO 63110, USA
2
Mallinckrodt Institute of Radiology, Washington University School of
Medicine, St. Louis, MO 63110, USA
Full list of author information is available at the end of the article

diagnosed with Wolfram syndrome will ultimately develop all four of the clinical conditions. Other features of
Wolfram syndrome include bladder and bowel dysfunction, temperature dysregulation, gait abnormalities, and
loss of the senses of smell and taste. Wolfram syndrome
symptoms have a negative impact on individuals’ daily
function and quality of life [1, 2]. Symptoms of Wolfram
syndrome usually start in the first two decades of life
and progress over years [3]. Currently, there is no treatment to stop the progression of the disease, and many
symptoms can be life-threatening [1, 3].
Two genetically distinct variants have been identified, type-1 and type-2 Wolfram syndrome, which
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result from mutations in the WFS1 and CISD2,
respectively [4, 5]. Type-1 Wolfram syndrome is
much more common [4, 6]. Type-2 Wolfram syndrome presents with the four primary features of type
1 Wolfram syndrome, with the additional features of
gastrointestinal ulcers, platelet dysfunction, and absence of diabetes insipidus [6]. Interestingly, mutations in the WFS1 are not implicated only in the
pathogenesis of classic Wolfram syndrome, but are
also involved in the development of other WFS1-related disorders such as DFNA6/14/38 (OMIM
#600965) non-syndromic low-frequency sensorineural
hearing loss, non-syndromic autosomal-dominant diabetes, and Wolfram-like syndrome (OMIM #614296)
[7–9]. Syndromes that have mutations in WFS1 but
do not meet the diagnostic criteria of Wolfram syndrome (diabetes mellitus and optic atrophy) are referred to as WFS1-related disorders. WFS1 encodes
for a putative endoplasmic reticulum (ER) protein
called wolframin [10]. Since its discovery, growing
evidence suggests that wolframin plays a crucial role
in the regulation of ER stress and Ca2+ homeostasis
and that its deficiency triggers proapoptotic pathways
leading to cellular loss [11–13].
Wolfram syndrome can be associated with significant
neurological and psychiatric complications. Patients with
Wolfram syndrome experience a wide range of neurological complications including cerebellar ataxia (most
common), gait and balance abnormalities, and as the disease progresses, difficulty swallowing, nystagmus, memory loss, speech difficulties, seizures, and personality
changes [14, 15]. Neurological manifestations were
thought to appear at later stages of the disease, but recent evidence indicates some of these neurological abnormalities are present even at young ages [16, 17].
Besides these neurological complications, several psychiatric manifestations, including anxiety and depression,
can also occur early in the course of Wolfram syndrome
[16, 18, 19]. The molecular pathophysiology underlying
the neurological and psychiatric manifestations of Wolfram syndrome is not well understood. In general, the
field is hampered by a lack of a viable conceptual framework and thus is missing hypothesis-driven experimentation focused on the central nervous system impact of
WFS1 mutations [20–22].
In this review, we attempt to summarize our current understanding of the Wolfram syndrome-related structural
and functional brain alterations and to provide insights
from new neuroimaging and WFS1 expression analyses
across age and cell types. We highlight similarities and differences compared to other neurodevelopmental and
white matter diseases of childhood. Together, this information suggests that Wolfram syndrome could belong to
a category of neurodevelopmental disorders characterized
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by ER stress-mediated myelination impairment. However,
studies investigating the roles of WFS1 in myelinating oligodendrocytes are limited, and further histopathological
and molecular genetic studies are necessary to confirm
this hypothesis.

Molecular mechanisms in Wolfram syndrome
WFS-1/CISD-2 genes and Wolframin protein

The pathogenesis of Wolfram syndrome is attributed to
genetic mutations in two genetic loci on chromosome 4
(WFS1 and CISD2- also known as ZCD2 gene or WFS2
gene) [4, 5]. WFS1 encodes an endoplasmic reticulum
(ER)-associated transmembrane glycoprotein called wolframin. Wolframin seems to play a role in the regulation
of cellular and ER Ca2+ homeostasis, and to contribute
to quality control systems for protein folding and regulation of the ER stress response [11–13]. Loss of function
mutations of wolframin triggers a cascade of ER and
mitochondrial dysfunction that ultimately leads to apoptosis and cellular death. On the other hand, CISD2 encodes for an ER intermembrane small protein (ERIS), a
protein expressed on the mitochondria-associated ER
membranes (MAMs). Mutations in CISD2 alter Ca2+
flux between ER and mitochondria, disrupting organelle
function, and leading to autophagy and cell death like
that seen in several other neurodegenerative diseases.
Different mutations in WFS1 likely result in different
disease phenotypes, but genotype-phenotype relationships are not yet fully understood [3, 23]. Moreover, a
novel CISD2 mutation was discovered recently in a patient with the Wolfram syndrome type 1 classical phenotype, suggesting that type 1 and type 2 Wolfram
syndrome could be viewed as a continuous clinical
spectrum with overlapping phenotypes, providing a clue
that the protein products of WFS1 and CISD2 may reside in the same molecular pathway [24]. A summary of
the molecular pathways involved in Wolfram syndrome
is shown in Fig. 1.
Role of WFS1/CISD2 in ER stress and unfolded protein
response (UPR)

Some authors have considered Wolfram syndrome to be a
monogenic prototype of human ER disease and the best
human disease model for investigating biomarkers and
therapeutics associated with ER health [25]. Disturbances in
Ca2+ homeostasis and the buildup of misfolded proteins in
the ER leads to a condition called ER stress, which has been
implicated in the pathogenesis of several neurodegenerative
diseases [26, 27]. ER stress triggers an adaptive intracellular
pathway, called the unfolded protein response (UPR), which
attempts to restore ER homeostasis, by attenuation of general protein translation and increase of the ER capacity of
protein folding [28]. However, in cases of chronic and unresolved ER stress, the UPR initiates proapoptotic pathways
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ERIS and multiple UPR effector proteins are indeed located in the mitochondria-associated membranes
(MAMs). Taken together, these findings strongly suggest
a potential interaction between ER homeostasis and
mitochondrial dynamics [35–37].

Fig. 1 A schematic representation of the endoplasmic reticulum and
mitochondrial molecular changes in Wolfram syndrome (the red box
indicate a deficiency of this protein). ER: endoplasmic reticulum; ATF6:
Activating transcription factor 6; UPR: unfolded protein response; WFS1:
wolframin protein; CISD2: CISD2 protein product, ERIS

leading to cell death [29]. Given its localization in the ER,
wolframin seems to play a crucial role in ER Ca2+ homeostasis, as well as regulation of the ER stress and the UPR,
and mutations in WFS1 have been shown to induce ER
stress-mediated neuronal loss [10, 22, 25, 30]. On the other
hand, CISD2 seems to play a less critical role in ER stress
pathways, and some scientists suggest that type 2 Wolfram
syndrome is actually a mitochondrial disease rather an ER
stress-mediated condition [31].
Mitochondrial dysfunction in Wolfram syndrome

It has long been appreciated that several neurological
and psychiatric manifestations in Wolfram syndrome resemble those observed in mitochondrial disorders [32].
Therefore, some authors have suggested that mitochondrial dysfunction is the primary underlying cause of
neuronal cell loss in Wolfram syndrome [31, 33, 34].
Specifically, Cagalinec et al. showed that wolframin deficiency results in delayed neuronal development due to
pervasive alteration in mitochondrial dynamics like
inhibited mitochondrial trafficking and fusion, as well as
increased mitophagy – i.e., auto-degradation of the mitochondria [34]. The authors also demonstrated that the
alterations in mitochondrial function result from disturbances in cytosolic Ca2+ concentrations or could be a
direct result of increased ER stress. The communication
between ER and mitochondria is essential for cellular
Ca2+ homeostasis and disruptions of this communication
has been implicated in other neurodegenerative conditions [35]. These observations are not surprising since

Brain histopathology in Wolfram syndrome
Neuropathological studies provide a critical step towards
identifying brain regions and structures involved in
Wolfram syndrome. A handful of postmortem brain
histopathological case studies have been reported (Table 1)
[38–41]. However, the reported cases vary in age, the cause
of death, and in the scope of methods and tissues examined. Consistently, the most affected brain regions in Wolfram syndrome are the sensory pathways, the brainstem,
the cerebellum and the hypothalamus (Fig. 2) [38–41]. In
the visual system, the optic nerves appear grossly atrophic
and microscopic examination reveals loss of retinal ganglion neurons and myelinated axons throughout the visual
pathways with relative preservation of the visual cortex
[38–41]. Within the auditory pathway, studies have found
loss of the organ of Corti (the functional unit of the inner
ear) in the basal turns of the cochlea, fibers in the cochlear
nerve, and neurons in the cochlear nuclei and inferior colliculus [39, 40]. Within the olfactory pathway, atrophy of
the olfactory bulb and tract has also been reported [39].
The brainstem and cerebellum are grossly smaller in Wolfram syndrome. Microscopic examination finds moderate
neuronal loss and gliosis in almost all brainstem nuclei
(pontine nuclei, raphe nuclei, inferior olivary nuclei, medial
vestibular nucleus, medullary and pontine reticular formation, vagus dorsal nuclei, ambiguous nuclei) [39–41]. In the
cerebellum, microscopic evidence of neuronal loss in the
dentate nuclei and reduction of Purkinje cells is variably reported and has been an inconsistent finding in these case
studies [39–41]. The hypothalamus exhibits significant gliosis and severe loss of magnocellular neurons in the supraoptic and paraventricular nuclei (a group of neurons that
project to the posterior pituitary and are responsible for the
release of oxytocin and vasopressin) [39–41]. Other brain
structures are affected to a lesser extent. For example, the
thalamus has been reported to have mild neuronal loss and
gliosis in the anterior and dorsomedial nuclei [39]. Other
less frequently reported findings include mild axonal damage in the calcarine cortex, mild motor neuron loss and
gliosis in the spinal cord, and loss of pigment, neuronal loss,
and gliosis in the substantia nigra [38, 39].
From all these case studies, it might be said that there
are two distinct histopathological abnormalities associated with Wolfram syndrome: neuronal loss and gliosis
in subcortical and limited cortical gray matter, and
patchy demyelination and axonal degeneration in several
white matter tracts, e.g., optic radiation, pontocerebellar
and corticopontine tracts, hippocampal forncies, and the
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Table 1 Summary of the histopathological findings in Wolfram syndrome patients
Reference Patient Clinical Findings

Histopathological findings

Carson
15 yo
et al. 1977 M

DM, DI, OA, osteopetrosis, and obstructive uropathy.

- Atrophy of the pons, optic nerves, chiasm, and tracts, pale SN,
and small posterior pituitary
- Axonal destruction and loss of myelin in optic nerves, chiasm,
and tracts, CST and transverse pontine fibers. Loss of neurons
in the PVN and SON.

Carson
21 yo
et al. 1977 F

CHD and renal anomalies, vision loss, DM, DI, and
osteoporosis

- Atrophy of optic nerves, chiasm, and tracts, pallor of the OR, pale
SN, absent posterior pituitary, atrophy of pons and cerebellum
- Severe axonal destruction and demyelination in optic nerves, loss
of neurons in the PVN and SON, gliosis/atrophy of the superior
olivary nucleus, scattered regions of demyelination.

Hilson
24 yo
et al. 2009 M

DM, DI, vision loss, Hashimoto thyroiditis, nystagmus, SNHL,
slurred dysarthria, gait abnormality

- marked neuronal loss in the PVN and SON, pontine base, inferior
olivary nucleus, retinal ganglion, myelinated axons in the optic
nerves, optic chiasm, lateral geniculate nucleus, and loss of organ
of Corti in the basal turn of the cochlea

Genis
37 yo
et al. 1997 F

DM, anosmia, vision and high-frequency hearing loss, cere
bellar dysfunction, clonus, memory loss, dysarthria, postural
tremor, and urinary abnormalities

- Atrophy of olfactory bulbs, tracts, optic nerves, chiasm, loss of
neurons in LGN, superior colliculus, cochlear nerve and nuclei,
inferior colliculus, and OPCT atrophy, demyelination of the
pyramidal tracts, neuronal loss of the PVN and SON, and motor
neurons in the spinal cord

Shannon 38 yo
et al. 1999 F

DM, DI, vision loss, SNHL, hyporeflexia, urinary abnormalities, - Degeneration of optic nerves and tracts, loss of neurons in LGN,
paresthesias, memory impairment, anosmia, strabismus,
basis pontis, PVN and SON, widespread axonal dystrophy in
nystagmus
pontocerebellar tracts, OR, hippocampal fornices, and deep
cerebral white matter

DM diabetes mellitus, DI diabetes insipidus, OA optic atrophy, SN substantia nigra, PVN paraventricular nucleus of hypothalamus, SON supraoptic nucleus, CST
corticospinal tract, CHD Congenital heart disease, OR optic radiation, SNHL sensory neural hearing loss, LGN lateral geniculate nucleus, OPCT
olivopontocerebellar tract

Fig. 2 Brain structures and tissues most prominently affected in Wolfram syndrome. SON: supraoptic nucleus; PVN: paraventricular nucleus
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deep cerebral white matter [38–41]. It was suggested
that the axonal pathology is an independent process and
sometimes more striking than the neuronal loss, which
indicates that these could be independent pathological
processes [41]. Moreover, we have suggested that, if the
cases are arranged according to patient’s age and the severity of the disease, one might conclude that the evolution of the neuropathological alterations follows a
specific pattern from restricted myelin and axonal loss
to widespread myelin, axonal and neuronal loss [42].
This information could support our hypothesis that abnormal myelination and axonal pathology might precede
the neuronal loss. Of note, these conclusions need to be
viewed with caution since these histopathologic studies
were all published before the era of genetic confirmation
for Wolfram syndrome.

Quantitative neuroimaging in Wolfram syndrome
In vivo brain imaging provides a useful tool to assess the
histopathological abnormalities in various neurological
disorders across time, and without need for postmortem
tissue. In Wolfram syndrome, several brain MRI abnormalities are readily detectable by eye [15, 43]. However,
until recently, brain imaging findings were exclusively
studied in the relatively late stage of the disease, and as
case studies without quantification of the findings or
comparison with control groups [15, 43]. In adults, the
classical neuro-radiological manifestations of Wolfram
syndrome include marked atrophy of the brainstem, diffuse cerebellar gray and white matter atrophy, thinning
of the middle cerebellar peduncle, absent posterior pituitary T1 bright spot (indicating posterior pituitary degeneration), and optic nerve and optic tract atrophy [15, 43,
44]. Less frequently, MR images show signs indicative of
diffuse mild cerebral atrophy, periventricular white matter and ventral pons T2-weighted and fluid attenuation
inversion recovery (FLAIR) signal intensity changes,
empty sella, and abnormal T2-weighted signal in the
substantia nigra [40, 45–47]. Most of these MRI findings
were also observed in children with Wolfram syndrome,
and as early as the immediate postnatal period in one
case of congenital diabetes insipidus [48]. Another remarkable finding in Wolfram syndrome is the discrepancy between the radiological and neurological
manifestations in some instances, i.e., marked radiological changes with no or minimal neurological dysfunction [43].
The most comprehensive attempt to characterize the
structural neuroimaging phenotype in Wolfram syndrome patients, at a relatively early stage, was conducted
by our group [16, 42, 49]. Our goal was to quantify regional brain volume and microstructural abnormalities
associated with Wolfram syndrome. A summary of these
structural neuroimaging findings is shown in Table 2
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and Fig. 3. In brief, the intracranial and whole brain volumes, brainstem, cerebellar white and grey matter volumes were lower in Wolfram syndrome when compared
to controls (using both region of interest (ROI) and
voxel-wise analysis approaches) [16]. The thalamus and
pallidum also showed a mildly lower volume but no differences in the volume of striatal structures (putamen,
caudate, and nucleus accumbens), hippocampus and
corpus callosum [16, 49]. Brainstem volumes were reduced in all segments (midbrain, pons, and medulla) but
the difference was most striking in the pons [16, 49]. Reduced cortical thickness was a less prominent finding
with the pre-central, lingual, and middle frontal regions
mostly affected [16]. White matter microstructure was
also examined using diffusion tensor imaging (DTI).
Wolfram syndrome patients had significantly lower fractional anisotropy (FA) and higher radial diffusivity (RD)
in widespread white matter tracts (optic radiation, middle cerebellar peduncle, inferior fronto-occipital fasciculus, and acoustic radiation) compared to age-equivalent
controls [49]. FA is a highly sensitive measure of overall
WM microstructural integrity [50, 51] and RD measures
water diffusion perpendicular to the principal axonal
axis, which is used as a surrogate marker for myelination
[51]. The combination of higher RD and lower FA observed in the Wolfram group could indicate impaired
myelination in these patients.
Recently, we also examined changes in brain volumes
over time in Wolfram syndrome compared to controls.
Using voxel-wise morphometric longitudinal analyses, we
found that specific white and gray matter volumes were affected during development in Wolfram syndrome [42].
Over time and age, white matter volumes tend to increase
in controls, reflecting increased myelin, and gray matter
volumes tend to be stable (subcortex) or decrease (cortex).
In contrast, patients with Wolfram syndrome had stable (in
optic radiations) or decreasing (in brainstem, ventral pons)
white matter volumes and more sharply decreasing volumes in the thalamus and cerebellar cortex. These findings
are consistent with stalled or deficient myelination during
development in Wolfram syndrome and subsequent or
simultaneous excessive loss of axons and cell bodies over
time [42]. Importantly, it seems unlikely that the brain abnormalities described in Wolfram syndrome patients are
the consequence of diabetic complications. In the previous
studies, Wolfram syndrome patients were compared to
healthy and type 1 diabetic controls with comparable glycemic profiles, yet Wolfram syndrome patients were qualitatively different from both control groups [16, 42, 49].
In contrast to these structural studies, functional neuroimaging studies in Wolfram syndrome are relatively
lacking. To date, only one study has quantitatively investigated functional brain changes in Wolfram syndrome.
This study showed regional differences in glucose uptake
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Table 2 Summary of the quantitative neuroimaging findings in Wolfram syndrome patients
Reference

Neuroimaging findings

Analysis type

Brain volumes
Hershey et al. - ↓ Intracranial and whole brain volume
2012 a
- ↓ brainstem (midbrain, pons, and medulla) volumes; most striking in pons

Lugar et al.
2016 a

Lugar et al.
2019 a

ROI

- ↓ GM volume in the cerebellum.

VBM

- ↓ WM volume in the cerebellum, brain stem, and subcortex

VBM

- ↓ total cortical WM and total subcortical GM volumes
- ↓ volume in ventral and dorsal pons, midbrain, medulla, cerebellar WM and GM, thalamus and pallidum

ROI

- ↑ amygdala volume

ROI

- WM volumes were stable (OR) or decreasing (brainstem and ventral pons)

ROI, VBM

- GM volumes were decreasing in thalamus and cerebellar cortex

ROI, VBM

Cortical thickness/cortical volumes
Hershey et al. - ↓ cortical thickness in pre-central region, lingual region, and two rostral middle frontal region
2012
Lugar et al.
2016

- ↓ cortical thickness and cortical volume in primary and secondary visual cortex; higher cortical volume
and surface area in the primary and secondary auditory cortex

ROI

- ↓ peri-calcarine region surface area, thickness, and volume; ↓ volume in parahippocampal region; ↑ tem- QDEC vertex-wise corporal lobe regions surface area and volume; ↑ rostral middle frontal volume and thickness
tical metrics
Diffusion MRI and white matter integrity
Hershey et al. - ↓ FA in the cerebellum and OR + ↓ MD in the cerebellum
2012
- Widespread ↓ FA and AD, mostly in the brainstem, cerebellum and OR
Lugar et al.
2016

ROI
TBSS

- ↓ FA and ↑ RD in OR, MCP, IFOF, and AR; and ↑ AD in OR

Tractography

- ↓ FA (CST, IFOF, OR, CC); ↑ RD (MCP, CST, ILF, OR, SLF); ↑ AD (MCP, IFOF, ILF, ALIC)

TBSS

a

Participants enrolled in these three studies overlap (Hershey et al. 2012: 11 Wolfram patient/ 54 type 1 diabetes and healthy controls; Lugar et al. 2016: 21
Wolfram patients/ 50 type 1 diabetes and healthy controls; Lugar et al. 2019: 29 Wolfram patients/ 52 type 1 diabetes and healthy controls)
GM gray matter, WM white matter, ROI region-of-interest, VBM voxel-based morphometry, QDEC Query, Design, Estimate, Contrast, FA Fractional anisotropy, OR
optic radiation, MD mean diffusivity, AD axial diffusivity, RD radial diffusivity, TBSS tract-based spatial statistics, MCP middle cerebellar peduncle, IFOF inferior
fronto-occipital fasciculus, AR acoustic radiation, CC corpus callosum, CST corticospinal tract, ILF inferior longitudinal fasciculus, SLF superior longitudinal fasciculus,
ALIC anterior limb of internal capsule

measured by PET-CT scan in several brain regions, most
notably the occipital lobe and cerebellum [52]. The authors of this study suggested that functional alterations
in Wolfram syndrome may precede detectable structural
changes.

Neurodevelopment and Wolfram syndrome
Evidence that WFS1 could play a vital role in brain development comes from several clinical, neuroimaging,
and genetic observations, yet the role that WFS1 plays in
the healthy developing brain is not completely understood. Clinically, manifestations of Wolfram syndrome
have been reported as early as the intrauterine and early
postnatal life in a child with neonatal-onset congenital
diabetes insipidus [48, 53]. Furthermore, Wolfram syndrome has even been associated with several congenital
anomalies including orbital bone and eye globe hypoplasia [53], neural tube defects like spina bifida [54], and
potentially, microcephaly [16, 40]. In the endocrine system, the role of WFS1 in organ embryogenesis has been
documented in the pancreas, specifically showing a
lower number of pancreatic islets in wfs-1 deficient mice

when compared to heterozygous and wild-type mice
[55]. Neuroimaging studies have also shown that Wolfram syndrome has a pronounced impact on early brain
development [16]. For example, Wolfram syndrome has
also been associated with other congenital brain anomalies like thinning or agenesis of the corpus callosum, congenital hypoplasia of the optic nerve, and absent
pituitary stalk [48].
Molecular genetic studies have shown that wolframin
deficiency may impair early neuronal survival and delay
neuronal development [34]. WFS1 is expressed during
brain development, and the downstream molecular pathways affected by wolframin deficiency (e.g., UPR and
mitochondrial dynamics) also play a crucial role in early
brain development, e.g., neurogenesis, neuronal migration, and myelination [34, 56, 57]. Although the UPR is
known to be activated during normal developmental
myelination, WFS1-dependent pathways in oligodendrocytes and astrocytes have never been investigated. WFS1
expression and function may, therefore, be different during development compared to adult life and understanding the patterns of gene expression in early life could
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Fig. 3 a) Sagittal and coronal view of a healthy young adult brain. b) Sagittal and coronal view of a young adult brain with Wolfram syndrome.
c) Significant volumetric differences between Wolfram syndrome and controls, controlling for whole brain volume. Regions that are smaller in
Wolfram syndrome are in light-blue, while regions that are larger are in yellow. d) White matter microstructure alterations in Wolfram syndrome
as measured by diffusion tensor imaging. Green: white matter skeleton created by tract-based spatial statistics skeletonization step; Blue: white
matter tracts with greater radial diffusivity in Wolfram syndrome; Yellow: lower fractional anisotropy; Red: white matter tracts with overlap of
greater radial diffusivity and lower fractional anisotropy is shown in red

provide relevant information about the disease pathogenesis. Taken together, Wolfram syndrome could be
considered a neurodevelopmental condition with neurodegeneration occurring in later stages of the disease.
Further studies are required to confirm the role of WFS1
expression in early brain development and how wolframin deficiency could influence neuronal cell differentiation and maturation.

Oligodendrocytes and myelination
The exact role of WFS1 in astrocyte and oligodendrocyte
function and the effects of wolframin deficiency in these
cell types are still not investigated. Experiments in all
studies that investigated the molecular mechanisms of
Wolfram syndrome were conducted in either neurons,
fiberoblasts, or pancreatic cells but not in glial cells or
oligodendrocytes As we explained above, recent neuroimaging studies suggest that abnormal myelin development is a primary neuropathological feature of Wolfram
syndrome observed from a young age [49]. One possible
explanation is that wolframin deficiency alters myelinating oligodendrocytes’ function and interferes with myelin development. Another explanation could be that ER
stress triggers oligodendrocyte death and facilitates myelin degeneration, as it does in Pelizaeus-Merzbacher

(PMD) and Vanishing White Matter Diseases (VWMD)
[49, 58, 59]. Moreover, in blood samples from patients
with Woflram syndrome, greater levels of cleaved myelin
basic protein (MBP), a major component of myelin
sheath, correlated with the severity of clinical symptoms
[49]. Although these observations support our hypothesis, it is possible that the abnormal myelination could
be related to underlying axonal pathology since the preservation of the myelin sheath requires the support of the
associated axons [60].
In the rodent brain, WFS1 is expressed in several central
nervous system (CNS) regions including cerebral and
cerebellar cortex, amygdala, CA1 field of the hippocampus, hypothalamus, basal ganglia, and several brainstem
nuclei [10, 20, 61]. Moreover, WFS1 is also ubiquitously
expressed in retinal ganglion cells and optic nerve glial
cells [62, 63]. However, expression patterns of WFS1 differ
in regional and temporal relations in postnatal development [61]. Kawano et al. suggested that WFS1 could have
functional significance in the development and maintenance of neurons in the hypothalamic nuclei, the auditory
system including the cochlea, and the cerebellum. It is intriguing that WFS1 expression is observed in widespread
CNS regions while the neuronal loss is only observed in
specific structures like cerebellum, optic pathway, and
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brainstem. It is tempting to speculate that the neurons less
affected by WFS1 mutations could have, a yet unknown,
functionally-related protein or pathway to compensate for
wolframin deficiency and could explain the preferential
vulnerability in certain brain regions. Taken together,
WFS1 expression patterns in various brain structures
could inform knowledge relevant to the neurological and
psychiatric symptoms observed in Wolfram syndrome.
Oligodendrocytes (the myelinating cells of the CNS)
play a crucial role in the development and maintenance
of axonal integrity, providing metabolic support through
the myelin sheath [64]. Oligodendrocytes produce
massive amounts of plasma membranes and transmembrane proteins during the myelination process making
them especially vulnerable to secretory pathway disruptions [65]. Previous studies have shown that UPR activation in actively myelinating oligodendrocytes triggers
apoptosis and cell death [66]. It is possible that wolframin deficiency in actively myelinating oligodendrocytes
leads to activation of the UPR, resulting in oligodendrocyte death and abnormal myelination. Unfortunately, the
roles of WFS1 and wolframin protein in the oligodendrocytes have never been investigated. We hypothesize
that WFS1 plays an essential role in oligodendrocyte
function. To begin to investigate the hypothesis that
WFS1 plays an essential role in oligodendrocyte function, we performed an exploratory analysis of WFS1 expression in development and across specific cell types.
WFS1 gene expression

To better understand the temporal and spatial expression
of WFS1 in the brain, we examined WFS1 expression in
data from the BrainSpan Atlas of the Developing Human
Brain (http://www.brainspan.org), a publicly available
human-brain genomic database maintained by the Allen Institute [67]. We constructed heatmaps both before (Fig. 4a,
left) and after (Fig. 4a, right) a normalization of gene expression, which was performed by dividing each region’s
WFS1 expression in a certain time period (e.G. striatum at
8-15 yrs) by the maximum expression value which that region displays across time periods. The pre-normalisation
heatmap enables comparison of relative WFS1 expression,
while the normalized heatmap displays more dynamic
range for within-region comparisons. When normalized to
maximum signal in each region and classified by age, WFS1
was found to be most highly expressed in the human brain
from 8 to 15 years of age (Fig. 4a), suggesting that WFS1
may be most active in early brain development rather than
in adulthood. Previous studies have indicated that this late
childhood and early adolescence period overlaps with a
period of active myelination in development. The period of
most rapid myelination varies depending on specific cortical and subcortical regions, but dynamic change in myelination has been observed in pre-adolescence and

Page 8 of 14

adolescence in the hippocampal formation [69]. Increases
in myelination have also been reported in the adolescent
time period in motor and cingulate cortices [70], while another study observed myelination during development in
frontopolar and visual neocortex but not motor and somatosensory cortices in adolescence [71]. The expression of
WFS1 and correlated gene sets in certain cell populations
can also be examined using the Cell-type Specific Expression Analysis (CSEA) tool (http://genetics.wustl.edu/jdlab/
csea-tool-2/) [68]. Leveraging gene sets from human genetic
data or gene expression specific to human or mouse populations, the CSEA tool suggests neural populations that
may be disrupted in specific neurogenetic disorders, and by
extension what circuits might be of interest in further
mechanistic studies. The CSEA tool uses cell-type specific
profiling data to evaluate how disease-related genes and
transcripts are enriched in candidate cell populations [72].
To further investigate WFS1’s role in healthy human brain
development, we therefore compiled data regarding WFS1
expression patterns by obtaining the top 352 genes coexpressed with WFS1 in the BrainSpan Atlas of the Developing Human Brain. Many functionally related genes are
co-expressed, therefore an examination of genes spatially
and temporally expressed with WFS1 may provide functional insights into WFS1’s role in the brain. Co-expression
with WFS1 of each gene in the BrainSpan database was calculated by examining expression levels in 35 human participants (starting as young as 8 weeks post-conception) and in
each of their brain regions for which gene expression data
was available. For age-specific analyses, only the subset of
samples which originated from individuals within the age
parameters was analyzed. The Pearson correlation coefficient between WFS1 and each gene’s overall expression
across all samples was then calculated and ranked to select
the group of genes most highly co-expressed with WFS1
for further analysis. To replicate this pattern, we also queried the top 304 genes co-expressed with WFS1 in the BrainCloud application (http://braincloud.jhmi.edu/), which
provides a database of gene expression data in the human
prefrontal cortex from 14 gestational weeks to 78 years of
age [73].
Using CSEA to evaluate the 296 genes in our Brainspan
dataset that existed in the cell-type expression dataset, we
identified that WFS1-correlated genes are enriched in cell
populations that include astrocytes and oligodendrocytes in
both the cortex and cerebellum, as well as Bergmann glia
and oligodendrocytes in the cerebellum (Fig. 4b). Interestingly for our development hypothesis, enrichment also
seemed to occur in oligodendrocyte progenitors. Analysis
of the 224 genes from our BrainCloud-derived WFS1-related gene set that existed in the CSEA expression dataset
corroborated the finding of cell-type specific enrichment in
oligodendrocyte and astrocyte populations, as well as cerebellar Bergmann glia and oligodendrocytes (Fig. 4c;
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Fig. 4 Temporal expression of WFS1 and cell type-specific expression of WFS1-related genes. a) Left: Mean WFS1 spatiotemporal expression
(RPKM, or reads per kilobase per million) in 16 brain regions and 5 developmental time periods from the BrainSpan database (8–26 postconception weeks (pcw), 4 months-4 years, 8 years–15 years, 18 years–23 years, and 30 years–40 years). Right: Mean WFS1 spatiotemporal
expression normalized to each brain region’s expression across time. b) Cell-type specific expression in the human brain of WFS1-related genes.
Gene list derived from BrainSpan database brains 8pcw-40 yrs. c) Cell-type specific expression in the human brain of WFS1-related genes, derived
from the BrainCloud database (prefrontal cortex). d) Cell-type specific expression in the human brain of WFS1-related genes. Gene list derived
from BrainSpan database, ages 4 months-4 years. e) Key to CSEA map. Hexagon size is scaled to gene list length, and each concentric ring
corresponds with specificity index threshold (pSI) which decreases as the number of relatively enriched transcripts decreases and the remaining
subset is relatively more specific. Map key reprinted with permission from [68]

Additional file 1). Surprisingly, inclusion of astrocytes as a
cell type of interest also raises the possibility that astrocytic
ER stress or glial-wide impairment may also play a role in
myelination alterations and brain changes observed in Wolfram syndrome. However, the exact role of astrocytes in
WFS1-related disease has not been studied previously and
is beyond the scope of this review.
Age-specific analysis of WFS1-related gene expression in the 4 months to 4 year time period overlapping with the myelination window also suggested a
strong link to glial processes in both CSEA and gene
ontology findings. When gene expression was broken
down to look at cell-type specific expression across
age (Additional file 2), CSEA analysis of the 280
WFS1-related genes in the CSEA dataset and derived
from the BrainSpan database also revealed enriched
expression in glial cells and oligodendrocyte progenitors in the 4 month to 4 year range (Fig. 4d), again
suggesting that WFS1 is implicated in development
and preferentially expressed in glia including oligodendrocytes. Gene ontology (GO) analysis of this 4
month-4 year WFS1-related gene set using BiNGO, a
biological network gene ontology tool (https://www.
psb.ugent.be/cbd/papers/BiNGO/Home.html)
[74],
and the EBI Gene Ontology Annotation Database
(2019-03-18 release) [75, 76], also recovered oligodendrocyte- and glia-related terms such as oligodendrocyte differentiation, axon ensheathment,
ensheathment of neurons, myelination, gliogenesis,
glial cell differentiation, oligodendrocyte development, and glial cell development which were within
the top 10 most statistically overrepresented biological processes at this age (p < 9E-11, FDR corrected, Additional file 3). Taken together, these gene
expression data suggest a role for WFS1 in myelination by the gene’s co-expression with transcripts
characteristic of these cell types and by the gene’s
peak expression during developmental periods related to glial maturation. While this co-expression
analysis is intriguing, careful work in genetically
tractable experimental systems will be needed to determine if WFS1 mutation is acting directly in glia
or indirectly in a non-cell autonomous manner on
these maturation processes.

Neuroimaging in other CNS disorders compared
to Wolfram syndrome
Given our neuroimaging findings, suggestions from
neuropathological case studies, and our WFS1 expression analyses, we propose that Wolfram syndrome could
be classified as a developmental hypomyelinating condition, characterized by reduced or absent myelin development [77]. As mentioned in the previous section, this
group of disorders includes PMD and VWMD. The
quantitative neuroimaging findings in PMD and VWM
resemble the findings observed in Wolfram syndrome
[78, 79]. For example, DTI studies of PMD show widespread decrease in FA and increase in RD, just as we see
in Wolfram syndrome [78]. In addition, these hypomyelinating conditions also have cerebellar atrophy, signal
abnormalities in the pons, and T2 lesions in the deep
white matter [79]. Nevertheless, the signal intensity abnormalities (presumably reflecting defective myelination)
observed in PMD and VWM are more extensive, often
symmetrical, and appear earlier in life compared with
the changes observed in Wolfram syndrome. Furthermore, the clinical course in hypomyelinating condition,
unlike Wolfram syndrome, is more precipitous with progressive deterioration of cognitive and motor function
occurring in the first and second decades of life. Assessment of myelin deficit in Wolfram syndrome using advanced techniques like magnetization transfer imaging
(MTI) and myelin water fraction imaging could elucidate
additional information about the specific myelin alterations associated with Wolfram syndrome.
The brain atrophy and the changes in signal intensity
patterns in Wolfram syndrome also resemble the patterns observed in another group of rare disorders involving the pontocerebellar tract, e.g., olivopontocerebellar
atrophy (OPCA), multiple system atrophy (MSA), and
familial spinocerebellar degeneration [14, 43, 80–82].
Specifically, both Wolfram syndrome and OPCA show
atrophy involving the cerebellum, pons, and middle cerebellar peduncles with relative sparing of the pyramidal
tracts [82]. However, the severity and chronology of the
clinical manifestations can be widely different between
these conditions. For example, the age of onset in sporadic cases of OPCA and MSA is usually in the fifth or
sixth decade, while the neurological manifestations in
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Wolfram syndrome can be evident in the second decade.
The preferential involvement of the middle cerebellar
peduncle is a striking shared feature between OPCA and
Wolfram syndrome. It is intriguing to know that the
cerebellum and brainstem have a neurobiologicallylinked course of development with preferential susceptibility to neurodevelopmental disorders [83, 84]. Besides,
this specific pattern of degeneration and neuronal loss in
the basilar part of the pons, cerebellum, and inferior
olivary nuclei is observed in several neurodegenerative
disorders like mitochondrial disease and olivopontocerebellar atrophy [85]. Several brainstem nuclei are closely
connected with the cerebellum and lesions in either one
can result in a degeneration of the other. Why these
structures are especially vulnerable in Wolfram syndrome is yet to be determined.

Conclusions
In summary, Wolfram syndrome is a neurological disorder
with features of abnormal brain development and neurodegeneration. Emerging evidence from neuroimaging and
molecular genetic studies indicates abnormal myelination
and oligodendrocyte dysfunction are important features of
the disease. Studies of WFS1 expression and function in
oligodendrocytes and glial cells are limited and could be
used to test our hypothesis. Despite the advances in describing the gross neurologic alterations in animal models
of Wolfram syndrome [86], animal models need to have a
well-described neurophenotype that parallels what is seen
in humans, particularly the developmental aspects. Another avenue to explore could be the study of human induced
pluripotent
stem
cells
(hiPSCs)-derived
oligodendrocytes from individuals with Wolfram syndrome, e.g., using oligocortical spheroids [87, 88]. This information could help us understand the geno-phenotype
relationship in Wolfram syndrome, identify myelin-related
biological markers for disease progression and treatment
response, and open the possibility to look into remyelination therapies as a potential intervention to stop neurological deterioration in Wolfram syndrome [76].
Furthermore, understanding how Wolfram syndrome affects brain structure and function could also help identify
potential connections between neurodevelopmental disorders and neurodegeneration.
Supplementary information
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Additional file 1. A list of the most highly correlated genes with WFS1
in BrainCloud database, available in CSEA dataset.
Additional file 2. Cell-type specific expression of WFS1 related genes in
the CSEA dataset and derived from the BrainSpan database across several
age groups.
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Additional file 3. A list of biological processes from Gene ontology
analysis of 4 month-4 years WFS1-related gene set using BiNGO, a
biological network gene ontology tool.
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